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Abbreviations
BCA Assay: Bicinchoninic acid assay
CSP: Circumsporozoite Protein
DLS: Dynamic Light Scattering
E. coli: Escherichia coli
EM or TEM: Transmission Electron Microscopy
F5c: Pandora F5c
F5de: Pandora F5de
FPLC: Fast Protein Liquid Chromatography
Hepes: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
His-tag: Histidine tag
HIV: Human Immunodeficiency Virus
IPTG: Isopropyl β-D-1-thiogalactopyranoside
LB: Luria-Bertani Broth or Medium
Mes: 2-(N-morpholino)ethanesulfonic acid
Ni-NTA: Nickel-nitrilotriacetic acid
OD: Optical Density
PCR: Polymerase Chain Reaction
SAPN: Self-Assembling Protein Nanoparticle
SARS: Severe Acute Respiratory Syndrome
SDS-PAGE: Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis
SOC: Super Optimal Broth with Catabolite Repression Medium
Tris: Tris(hydroxymethyl)aminomethane
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Abstract
Malaria is an infectious disease that affects several million individuals worldwide and is a
significant international public health issue. While there is currently a malaria vaccine in phase
III clinical trials, recent results demonstrate that it is only about 35% effective in reducing the
incidence of the disease [2]. The use of self-assembling protein nanoparticles (SAPNs) that
display epitopes of the repeat sequence of the circumsporozoite protein of Plasmodium
falciparum, the parasite that causes malaria, has been shown to elicit a strong immune response.
This prototype has potential for further improvement by altering the epitope regions of the
nanoparticles to be more compatible with humans and by modifying the nanoparticle backbone
to be more soluble and compact. It was predicted and demonstrated, through dynamic light
scattering and transmission electron microscopy imaging, that these slight changes to the
nanoparticle construct could result in increased stability and immunogenicity for this promising
malaria vaccine.
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Introduction
Malaria is an infectious disease that affects several million individuals worldwide.
According to the World Health Organization, malaria is endemic in more than 100 countries and
resulted in approximately 660,000 deaths in 2010 [1], making this disease a significant
international public health issue. While there is currently a malaria vaccine in phase III clinical
trials, recent results demonstrate that it is only about 35% effective in reducing the incidence of
the disease [2]. The use of self-assembling protein nanoparticles (SAPNs) that display epitopes
of the repeat sequence of the circumsporozoite protein (CSP) of Plasmodium falciparum, the
parasite that causes malaria, have been shown to elicit a strong immune response. This prototype
has potential for further improvement by altering the epitope regions of the nanoparticles to be
more compatible with humans and by modifying the nanoparticle backbone (trimeric and
pentameric coiled-coils) to be more soluble and compact. It is predicted that these slight changes
to the nanoparticle construct could result in increased stability and immunogenicity for this
potential malaria vaccine.
SAPNs are small proteins that assemble to form oligomers with diameters on the
nanoscale. Studying particles on the nanoscale has become exceptionally relevant in recent years,
especially in the area of rational drug design and vaccine development. This particular
nanoparticle design (figure 1A), which has proven effective for the potential development of
SARS and HIV vaccines [3, 4], involves the formation of an oligomer with icosahedral
symmetry (i.e. 20 planes with 2, 3, and 5 fold symmetry axes [5]) from sixty self-associating
identical protein monomers [6]. Each monomer contains a sequence that forms a pentameric and
trimeric coiled-coil backbone (figure 1B), connected by a one to two amino acid linker [6].
Importantly, these fully assembled nanoparticles have a general appeal in the area of vaccine

design, as their diameter is often on the same order as many viruses [5, 7]. Antigenic peptide
sequences, which, in this case originate from the Plasmodium falciparum sporozoite, can be
attached to each end of the backbone. These nanoparticles assemble into large globular
oligomers with many copies of the epitope exposed on the surface. Thus, such a design allows
for multiple opportunities for antigen presentation that could ultimately result in more significant
and longer lasting levels of immunity in the host organism.

To date, the most current SAPN vaccine prototype for malaria, known as PfCSP-KMYSAPN (figure 2A, B), exhibits three CD8+ T cell epitopes from CSP from Plasmodium
falciparum attached at the pentamer region of the protein and the universal CD4 T-helper cell
epitope incorporated into the trimer domain [8]. Also, attached to the C-terminal end of the
trimeric domain is the B-cell epitope (NANP4) from the repeat region of the CSP [8]. Thus, this
design has the capability of activating both humoral and cell-mediated immunity. Each protein
monomer also has a histidine tag at the pentameric, N-terminal end so that it can be purified
8

easily. This nanoparticle design with epitopes specific to mice (from Plasmodium berghei and
Plasmodium vivax), has been shown to result in a protective immune response by T-cell and Bcell proliferation especially in the liver and blood in Balb/c and related strains of mice [8]. This
study thus demonstrated that this particular SAPN design containing the CSP epitopes could
result in a protective immune response. Importantly, the vaccine formulation was administered to
the mice without addition of an adjuvant, demonstrating that the nanoparticles are capable of
eliciting an effective immune response without additional, supplementary stimulation of the
immune system. In this malaria vaccine design, and in others, the epitopes from CSP are
incorporated because CSP is especially relevant to the infection process of the host. CSP is
present on the surface of the sporozoites [9] that enter and infect the host upon being bitten by a
mosquito carrier and is a significant component in the infection process of the liver [9]. In this
particular vaccine design, the repeat region of CSP was incorporated into the protein monomer of
the self-assembled nanoparticle.

Because the PfCSP-KMY-SAPN prototype exhibiting the Plasmodium falciparum
(human malaria strain) CSP CD8+ epitopes can elicit an effective immune response in mice,
some modifications have been made to this design so that it can be further modified for humans.
In this new design, referred to as Pandora F5c (figure 3A), and additional fourth CD8+ epitope of
9

CSP has been incorporated in the trimeric region along with a new universal CD4+ helper T-cell
domain (specific to humans) in the trimer. Also, two amino acid replacements in the overall
protein trimeric and pentameric backbone were made, in order to achieve even greater solubility,
compactness, and stability in solution. The fully modified construct that was purified and
characterized herein is referred to as Pandora F5de (figure 3B). In the pentameric region of the
protein an arginine (residue 57) was replaced with a glutamic acid, making it more negatively
charged. Conversely, a glutamic acid (residue 93) in the trimer was switched with an arginine,
resulting in a more positively charged trimeric region. These changes were expected to promote
greater attraction between the two regions, so that the assembled nanoparticle would be more
compact in solution. Such considerations are exceptionally important as vaccine development
continues, due to the nanoparticle design itself, which is highly dependent on the geometric and
thermodynamic stability favoring the assembled state [7], and as a result of the requirements
associated with vaccine administration and efficacy in future in vivo studies [10]. The protein
monomer has a molecular weight of about 18 kDa and the correctly assembled SAPN with
icosahedral symmetry should be 1083 kDa. Furthermore, the estimated extinction coefficient of
the protein is 64, 940 M-1cm-1. Based on protein design and modeling methods, the approximate
diameter of the fully assembled SAPN is expected to be about 25 nm.
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The modifications, especially the two amino acid replacements of the two backbone
modifications, were made and the new protein monomer was expressed in Escherichia coli. The
protein was purified by affinity chromatography using a His-Trap column, as it historically has
resulted in especially pure proteins for similar constructs. Purification was conducted in
denaturing conditions (8 M urea), to achieve the greatest purity and to control the refolding
conditions once the monomer was purified. The refolding methods, buffer conditions, the general
shape, and affects of the applied modifications to the vaccine design described above were
evaluated by dynamic light scattering (DLS) and electron microscopy (EM) and compared to the
current design. Furthermore, experiments involving buffer effects on the size distribution of the
overall assembled nanoparticles and long-term storage at different temperatures were evaluated
by DLS. The use of DLS was important, because it allowed for the verification of the
approximate diameter of the nanoparticle oligomers, and it demonstrated the presence of any
aggregation or other obstacles that could prevent expected assembly of the monomer protein.
This is essential for vaccine development with this design, as only the fully assembled particle
would be able to elicit an immune response in the host, yet large aggregates would likely result
in a negative and undesirable immune response in vivo, such as anaphylaxis. EM was used to
evaluate the shape and size of the refolded and assembled nanoparticles under the various
conditions. It was hypothesized that these modifications to the current construct would improve
the malaria vaccine design and advance attempts to evaluate its efficacy in animal models.

11

Materials and Methods
Introduction of the First (R57E) Mutation. From the existing F5c plasmid, Pandora
F5de was prepared by introducing two mutations through PCR-mutagenesis and transformation
into DH5α Escherichia coli competent cells. PCR-mutagenesis was carried by combining 16 µl
of ddH2O, 2 µl of F5c plasmid (about 100 ng/µl), 0.5 µl of 10 mM dNTP mix, 1.5 µl of 10 uM
forward primer (5' TGG ATT GAC TGG CGT CGC GAC TGG CA 3’), 1.5 µl of 10 uM reverse
primer (5' CAA CGC TGG CCA GTC TTC ACG CCA GT 3’), 2.5 µl of 10x native Pfu buffer,
and 1 µl of 2-3 units/µl of Pfu DNA polymerase. The dNTP mix, Pfu buffer, and native Pfu DNA
polymerase were acquired from Stratagene and the primers were ordered from Integrated DNA
Technologies, Inc. A control without the F5c plasmid was also prepared. PCR was conducted
under heating for 5 minutes at 95C, 18 cycles of 30 seconds at 95ºC, 1 minute at 55ºC, and 5
minutes at 72ºC, and lastly 7 minutes at 72ºC. The plasmid was stored at 4ºC. The PCR product
was incubated with 1 µl of 20,000 units/ml of Type II restriction enzyme DpnI (acquired from
New England BioLabs) for 3 hours at 37ºC. The DNA was transformed into DH5α Escherichia
coli competent cells, by heat shock at 42ºC for 90 seconds. The cells were incubated with 800 µl
of SOC medium (from Q-Biogene) at 37ºC on a thermomixer (1000 rpm) for 1.5 hours,
centrifuged in a Beckman Coulter Microfuge 18 centrifuge at about 2000xg for 3 minutes, resuspended, and plated on LB agar (15 g agar/L LB broth, both from Fisher Scientific) with 100
µg/ml Kanamyacin. The plates were incubated at 37ºC for 16-18 hours.
Sequencing. Single colonies were re-streaked and grown in overnight culture with 30
µg/ml of Kanamyacin. The plasmid was purified from bacterial culture using the Pure Yield
Plasmid Miniprep System, from Promega, according to the manufacturer's protocol. DNA
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concentration was determined by Nanodrop scans at 260 and 280 nm. Plasmid was sequenced by
GeneWiz, Inc using the universal T7 primer.
Introduction of the Second (E93R) Mutation. The plasmid obtained from the first
mutation was used to introduce the second mutation. PCR-mutagenesis was carried out
according to the protocol described previously, with the exception that the forward (5' GTC
GAA GCG AAC CGC CGT GCC CTG GA 3’) and reverse (5' CAG TTC TTC CAG GGC ACG
GCG GTT CG 3’) primers corresponding to the second mutation were used. The PCR product
was transformed into BL21 E. coli competent cells; single colonies were re-streaked and DNA
was purified and sequenced as described above.
Expression. BL21 E. coli cells expressing the target protein were inoculated in LB media
with 30 µg/ml kanamyacin in a shaker at 180 rpm and 37°C [10]. The overnight culture was
added to one liter of LB media with 30µg/ml of kanamyacin and grown in a shaker at 180 rpm
and 37°C until it reached an O.D. of approximately 0.5 to 0.6 at 600 nm. At this point, isopropyl
β-D-1-thiogalactopyranoside (IPTG) was added to a final concentration of 1 mM [10], in order to
induce expression of the protein, and the culture was grown for an additional 4 hours. The cells
were spun down by centrifugation for 15 minutes at 4000xg in 4°C. Pellets were collected and
stored at - 80°C.
Protein Purification. The thawed pellet was suspended in lysate buffer (8 M urea, 100
mM NaH2PO4, 10 mM Tris, pH 8.0) and sonicated for 3 cycles of 5 minutes with 4 seconds of
sonication and 6 second gaps or until the solution is clear. The lysate was centrifuged at
30,600xg for 45 minutes, filtered, and degassed by vacuum. Purification was conducted by a
Nickel-NTA His Trap FF Column (from GE Healthcare) using the AKTA FPLC at room
temperature under denaturing conditions [10]. Once the column and the FPLC were pre-washed
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with sterile distilled water, the column was washed with approximately 15 column volumes of
binding buffer (8 M urea, 100 mM NaH2PO4, 10 mM Tris, 20 mM imidazole, pH 8.0). The
lysate was then loaded onto the column and the wash with binding buffer was continued for an
additional few column volumes. The column washed with 15 column volumes of wash buffer 1
(8 M urea, 100 mM NaH2PO4, 20 mM Na citrate, 20 mM imidazole, pH 6.8, 15 column volumes
of wash buffer 2 (8 M urea, 100 mM NaH2PO4, 20 mM Na citrate, 20 mM imidazole, pH 5.7),
and 15 column volumes of wash buffer 3 (8 M urea, 100 mM NaH2PO4, 20 mM Na citrate, 20
mM imidazole, pH 4.7). The column was further washed by 15 column volumes of elution buffer
1 (8 M urea, 100 mM NaH2PO4, 10 mM Tris, 250 mM imidazole, pH 8.0), and then by 15
column volumes of elution buffer 2 (8 M urea, 100 mM NaH2PO4, 10 mM Tris, 500 mM
imidazole, pH 8.0) [10]. All buffers were filtered and degassed. Purification was monitored by
change in conductance and by absorbance at 280 nm.
SDS-PAGE. The purification fractions were analyzed using Mini Protean TGX pre-cast
10 well 12% SDS gels from Bio-Rad. The samples for the wells were prepared by adding
Laemmli Sample Buffer (Bio-Rad) with β-mercaptoethanol to about 20 µl of each fraction, and
heated at 95°C for about 4 minutes. The gels were run for 30 to 45 minutes at 120 V and stained
using Coomassie Simply Blue SafeStain acquired from Invitrogen.
Quick Refolding. Dynamic Light Scattering (DLS) was performed in different buffers at
1:20 fold dilutions from the elution fractions that demonstrated the highest protein concentration.
Refolding in each buffer was achieved by diluting 50 µl of elution sample into 950 µl of buffer
and spinning for approximately 15 to 20 minutes. DLS was done on a Zetasizer Nano S
instrument (Malvern) with a 633 nm He-Ne laser [8]. The six buffers were: 1) 20 mM Tris, 40
mM NaCl, 5% glycerol, pH 8.5, 2) 20 mM Tris, 150 mM NaCl, 5% glycerol, pH 8.5, 3) 20 mM
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Hepes, 40 mM NaCl, 5% glycerol, pH 7.5, 4) 20 mM Hepes, 150 mM NaCl, 5%, glycerol pH
7.5, 5) 20 mM Mes, 40 mM NaCl, 5% glycerol, pH 6.5, and 6) 20 mM Mes, 150 mM NaCl, 5%
glycerol, pH 6.5 [5]. This provides a final urea concentration of 0.4 M. The measurements were
taken at room temperature.
Dialysis. The fractions with the greatest absorbance that also demonstrated the presence
of protein at the correct band on the gels were pooled and dialyzed in 1 liter of the optimal buffer
determined by quick refolding. A dialysis bag with a pore size of 8 kDa was used and dialysis
was carried out over a period of 24 hours, with a replacement of 1 liter of buffer after
approximately 12 hours. The protein was stored at -80°C in aliquots.
Concentration Determination. Nanodrop and BCA protein assay were used to
determine the concentration of the pooled elution fractions. With the Nanodrop, absorbance of
the sample was measured at 280 nm and concentration in mg/ml was calculated using the
extinction coefficient and molecular weight of the protein. The BCA protein assay was
performed according to the standard protocol of the BCA Protein Assay kit from
ThermoScientific. Absorbance measurements were taken at 620 nm on a plate reader and
concentration was determined by use of the graphed standard curve.
Direct Refolding. Aliquots of the protein samples were dialyzed in 20 fold dilutions of
each of the six buffers described above: 1) 20 mM Tris, 40 mM NaCl, 5% glycerol, pH 8.5, 2) 20
mM Tris, 150 mM NaCl, 5% glycerol, pH 8.5, 3) 20 mM Hepes, 40 mM NaCl, 5% glycerol, pH
7.5, 4) 20 mM Hepes, 150 mM NaCl, 5%, glycerol pH 7.5, 5) 20 mM Mes, 40 mM NaCl, 5%
glycerol, pH 6.5, and 6) 20 mM Mes, 150 mM NaCl, 5% glycerol, pH 6.5 [5]. These samples had
0 M concentration of urea. Refolding was conducted using the same methods described above
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and sample was analyzed with DLS at room temperature using the same instrument described
previously.
Stability Tests. The dialyzed protein was refolded into the four most optimal buffers and
7 aliquots of 500 µl of sample in each buffer were stored at 4°C for one month’s time [10].
Furthermore, dialyzed stock protein in the optimal buffer was placed at room temperature and at
4°C for one month. DLS measurements were taken, under the same condition described above,
for each experimental set up at days 0, 1, 7, 14, 21, and 28.
Transmission Electron Microscopy. Refolded protein samples were placed on a
FCF400 Copper Formvar Carbon Film (Electron Microscopy Sciences, Inc) Grid that was
charged using a Harrick Plasma Cleaner PDC-32G. The grid with sample was then stained with
1% uranyl acetate and washed with distilled water (negative staining). The sample was imaged
with a FEI Tecnai T12 S/TEM [8].
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Results
Protein Purification. Pandora F5de, the target protein, was purified using a Ni-NTA
column, since it contains a histidine tag. The column was washed with a pH gradient in order to
remove other proteins, impurities, and contaminants, such as nonspecifically binding molecules,
from the column. The protein eluted in 250 mM imidazole, as expected, in fractions 22 through
31, as evidenced by the large absorbance peak in this range (figure 4). Imidazole competed with
the histidines of the protein for binding with the nickel-bound beads, allowing the protein to fall
off the column. The large absorbance peak in fractions 1 and 2 indicated that the flow of protein
through the column once it was directly loaded. Progress of the purification and the equilibration
of the column with each buffer were monitored by change in conductance, as indicated by the
brown graph in figure 1. The SDS-PAGE gels (figure 5) demonstrated the presence of Pandora
F5de as the large band of protein at about 20 kDa in the lysate, flow through, and eluted fractions
22 through 31. Additionally, in the early fractions with washes at different pH levels, there was
evidence of elution of contaminant proteins. The gels indicated that the eluted target protein was
very pure, as there was no significant presence of other contaminants with one little exception:
The very faint band between 30 and 40 kDa could either be another protein from the bacteria that
contains exposed histidines or, more than likely, it was a dimer of the target protein. Given that
this band was predominantly in the sample with the greatest concentration of target protein, it is
likely that there was some dimerization. However, this is a matter that ought to be explored in
further studies, and will not be further dealt with here. Given the significant presence F5de in the
flow through, a larger column might have resulted in an even greater yield of protein. However,
for the purposes of these preliminary studies of the construct, the amount of purified protein
obtained was sufficient.
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Quick-Refolding. Since the purification was conducted under denaturing conditions, it
was essential to determine an appropriate buffer to dialyze the protein. Samples from fraction 29,
18

which had the highest absorbance peak (figure 4) and thickest band (figure 5), were tested under
six different refolding conditions. These conditions were tested because previous experience with
these constructs has shown that refolding can usually be achieved in one of the conditions. Since
significantly high concentrations of imidazole (250 mM) and urea (8 M) were present in the
sample from the purification, it was important to make dilutions (in this case 1:20) of the sample
into each buffer to determine the best buffer for refolding and storage. The dilutions resulted in
an approximate concentration of imidazole and urea at, 80 mM and 400 mM respectively.
Several scans from dynamic light scattering were used to indicate the approximate diameter of
each protein and to detect self-assembly and/or aggregation. The optimal buffer for refolding was
clearly 20 mM Tris with 40 mM NaCl at a pH of 8.5 (T40 buffer), as it resulted in the most
uniform distribution of particles and essentially no aggregation (figure 6E). In Mes, F5de
exhibited a great deal of aggregation, regardless of the salt concentration. In Hepes there was far
less aggregation than in Mes; however, it was not at all comparable to the distribution of
nanoparticles in Tris buffer. The diameter of the protein in T40 buffer was determined to be
22.03 nm, which was close to the expected value of about 25 nm. This indicated that the protein
was properly assembled into a symmetrical self-assembling structure, as expected. However,
since the diameter was slightly smaller, it is possible that the structure formed least common
multiple (LCM) units with 15 protein chains per particle, rather than the complete icosahedral
with 60 protein chains per particle. This would have to be determined by TEM. While there was
some aggregation in T40, which could be attributed to any number of factors, not least of which
the presence of imidazole and urea, the significant presence of assembled particle of this
diameter clearly indicated that 20 mM Tris, 40 mM NaCl, pH of 8.5 was the best buffer to use
for dialysis.
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Dialysis and Protein Concentration. Fractions 28, 29, and 30 were pooled, as they
contained the largest absorbance peaks and bands of the target protein, and dialyzed against one
liter of T40 buffer twice over a period of 24 hours. In this case, imidazole, urea, and other elution
buffer 1 components were diluted at least 10,000-fold, resulting in 8 mM urea and 0.25 mM
imidazole, which is essentially negligible compared to their previous concentrations. The pooled
and dialyzed protein concentration was determined to be 0.46 mg/ml by BCA Assay (figure
7A,B) and 0.58 mg/ml by absorbance scans with a Nanodrop spectrophotometer (figure 7B).
Given that the assays measure two different components related to protein structure and thereby
can be used to determine concentration, the discrepancy between the concentrations is not
necessarily surprising. The difference in concentration in this case, however, is not critical as this
information was only used to approximate the concentration of protein tested for direct refolding
and for electron microscopy.
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Direct Refolding. The pooled F5de in T40 buffer was dialyzed into each of the different
buffers and measurements were taken by DLS, which demonstrated that Tris buffer, whether at
40 mM or 150 mM NaCl, still remained the optimal buffer. While the Hepes buffer at low
concentrations of salt exhibited some aggregation and a lack of uniform protein assembly, Hepes
at high salt concentration did produce a uniform and properly assembled structure (figure 8C, D).
The diameter of the protein in 20 mM Hepes, 150 mM NaCl, pH 7.5 (H150 buffer) was found to
be 21.36 nanometers. In the Tris buffers, which seem to result in no aggregation and exhibit a
nearly uniform distribution of particles, demonstrated a nanoparticle diameter of 18.17 nm in
T40 buffer and 20.74 nm in T150 buffer. The slightly greater diameter in both buffers with
higher salt concentration might be due to the fact that high levels of salt can increase
hydrophobic molecular interactions and thus, either species with more protein chains per
assembly unit were formed (i.e. icosahedral particles versus LCM units) or particles started to
slightly stick together, as can be seen in the exceptional difference in particle distribution
between Mes buffer with 40 mM NaCl versus Mes with 150 mM NaCl (figure 8A, B) and
especially in Hepes with 40 mM NaCl versus 150 mM NaCl. However, this is a matter to be
explored in further studies that reach beyond the scope of these experiments.
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Stability Tests. The stability of the F5de nanoparticle construct was studied over the
period of one month (28 days). The purified protein that was already refolded in four different
buffers (H40, H150, T40, and T150) was measured by DLS once a week and stored at 4ºC.
Additionally, a sample of the nanoparticle in T40 buffer was placed at room temperature and at
4ºC and measurements were taken by DLS. The particles were overall very stable, as is evident
in figures 9, 10, and 11. In Hepes buffers, with some aggregation from the outset, it seemed that
there were measurable increases in aggregation of the protein over the course of one month.
Also, the assembled nanoparticle diameter exhibited significant increases in diameter, especially
in Hepes with the high salt concentration. The initial diameter of 20.0 nm more than doubled to
46.1 nm by the end of the month, and by day 7, the diameter was already 10 nm greater in
diameter than initially. This clearly indicates that aggregation occurred over time. In 20 mM
Hepes and 40 mM NaCl, however, over the course of the month the nanoparticle diameters were
22

19.9 nm on day 1, 23.69 nm on day 7, 24.46 nm on day 14, 24.46 nm on day 21, and 25.65 nm
on day 28. While the diameters were closer to the expected icosahedral nanoparticle diameter of
25 nm, the particles were not as uniform in distribution over the course of the month as in Tris
(figure 10). In the two Tris buffers, shown in figure 10, the nanoparticles appeared to be far more
uniformly distributed in solution. As the month progressed there was essentially no aggregation
over time. In 20 mM Tris with 40 mM NaCl, the initial diameter of 16.97 nm, was followed by
diameters of 23.03 nm on day 7, 19.76 nm on day 14, 15.94 nm from day 21, and 15.81 nm on
day 28. Just as in quick refolding (figure 6) and direct refolding (figure 8), Tris with 40 mM
NaCl appeared to be the buffer in which the nanoparticles were most uniformly assembled.
However, even though this was the case, these measured diameters were smaller than would be
expected for a fully assembled icosahedral nanoparticle, which might affect the immunogenicity
of the nanoparticles, since, in general, immunogenicity decreases for particles with a diameter
smaller than 20 nm. Tris with 150 mM NaCl seemed to result in less aggregation (figure 10A, B)
than any of the other buffers. Furthermore, in 20 mM Tris and 150 mM NaCl buffer the
nanoparticles exhibited the least variation in the hydrodynamic diameter, with 19.26 nm on day
1, 22.86 nm on day 7, 19.78 nm on day 14, 19.78 nm on day 21, and 19.44 nm on day 28.
Additionally, measurements taken over the course of a month in 20 mM Tris and 40 mM NaCl
from samples stored at 4ºC and room temperature indicate that there is essentially no difference
in the distribution of the nanoparticle sizes between the two temperatures (figure 11). Overall,
these tests demonstrate that the construct was exceptionally stable in Tris buffer, whether stored
at 4ºC or at room temperature. In both cases, the diameter of the nanoparticles throughout the
month was about 18 nm, indicating that the assembled nanoparticle maintained its shape and
stability for one month in both conditions.
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Transmission Electron Microscopy. Images of Pandora F5de were taken, at 120,000x
magnification, immediately upon refolding in 20 mM Tris, 40 mM NaCl, and pH 8.5 and then
after one month in the same buffer and in 20 mM Hepes, 40 mM NaCl, pH 7.5. The images in
Tris indicated the nearly uniform presence of partially assembled nanoparticles and appear to be
so-called LCM units with 15 protein chains per nanoparticle with some indications of slightly
larger more globular species, which would likely be a fully assembled icosahedral nanoparticle
(figure 12). This correlated with the DLS direct refolding data of smaller than expected
nanoparticle diameters discussed previously. Additionally, there were some white rod-like
structures in the images, which could have been contaminants in the buffer, the copper grid, or in
the uranyl acetate as these structures were also visible on EM grid preparations without protein.
The images from day one (figure 12A) showed more discrete individual particles, while the
images taken after one month (figure 12b) demonstrated closer association between particles due
to a higher protein concentration. Overall, though, the particle size and distribution was very
similar between the two, just as in DLS. The disparity in crispness between the two images was
likely due to differences in preparation and staining of the two grids. The image taken of F5de in
20 mM Hepes and 40 mM NaCl (figure 13) after one month indicated the presence of a more
heterogeneous species than was found in the images at pH 8.5. For the most part, the larger sized
particles appeared to be smaller sized particles associating, rather than formations of the
icosahedral nanoparticles, thus confirming the presence of LCM units. In Hepes, just as indicated
by the DLS, there was a far less homogeneous distribution and the indication of a nanoparticle
diameter closer to 25 nm, the expectation for the icosahedral species, was likely due to the
clumping of the smaller species over the course of one month, rather than formation of the fully
assembled nanoparticles.
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Discussion
According to the DLS and TEM data of the purified Pandora F5de construct, the protein
did self-assemble, but they did not form the complete icosahedrally symmetrical 60-mer
nanoparticle. Given that the hydrodynamic radius was approximately 20 nm or slightly smaller
and was uniformly distributed in solution, it can be inferred that the nanoparticles formed socalled LCM units with 15 protein chains per nanoparticle. The diameters of the nanoparticles
measured by DLS were slightly smaller than expected, sometimes around 16 to 18 nm, especially
in 20 mM Tris with 40 mM NaCl buffer. This smaller diameter could have been a direct result of
the switch in the charges (glutamic acid and arginine) in the backbone of the construct between
the negative pentamer and the more positive trimer, resulting in a more soluble and less
hydrophobic protein chain. The protein refolded exceptionally well in Tris buffer, both at high
and low salt concentrations and maintained its shape and uniformity, both according to DLS and
TEM, in solution for at least one month, both at 4°C and room temperature with no signs of
aggregation. The protein nanoparticle was evidently stable, which is an extremely important
consideration for vaccine development. However, since the nanoparticle size was smaller than
expected and the fully formed icosahedral species was not predominantly present in solution,
further studies will have to be performed in order to determine the immunogenicity of this
construct in its optimal refolding buffer.
The fact that the nanoparticles were uniform and stable, even if not a fully formed
icosahedral species, was very promising for using this construct and similar ones with this basic
design in malaria vaccine development. Given the similarity between this construct and PfCSPKMY-SAPN, which was discussed previously, it would likely exhibit the similar high levels of
immunity in vivo [8]. Furthermore, given the fact that in both cases CD8+ T-cell, B-cell, and
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CD4+ helper T-cell epitopes were incorporated into the nanoparticle constructs, F5de shares
similar potential for further development. For this to be the case, it would be necessary to further
purify the protein, using perhaps ion exchange chromatography and gel filtration, as has been
done previously when preparing a protein for in vivo studies [10]. Additionally, definitively
resolving the nature of the species that eluted, at very low concentration, with Pandora F5de
would be important. Also, a modification to the purification protocol that might have prevented
the elution of the species of about double the molecular weight of the target protein might have
been to elute with a linear gradient of imidazole, rather than directly with a concentration where
the protein was expected to elute. This would have allowed other potentially contaminating
proteins to elute earlier. As this construct was shown to be most stable at a relatively high pH
compared to physiological conditions, there might also be further interest in determining if the
construct can be refolded closer to a pH of 7, even though there were initial difficulties with 20
mM Hepes buffers at a pH of 7.5, by testing different excipients (such as e.g. trehalose or
sucrose) during refolding or testing conditions with even lower salt concentrations. These
potential modifications would most definitely be relevant to further studies of this construct, but
also for future analyses of these self-assembling peptide nanoparticle malaria vaccine prototypes.
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